Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease risk.

Christensen KD, Roberts JS, Uhlmann WR, Green RC.

Genet Med. 2011 May;13(5):409-14. doi: 10.1097/GIM.0b013e3182076bf1.

2.

The role of disease perceptions and results sharing in psychological adaptation after genetic susceptibility testing: the REVEAL Study.

Ashida S, Koehly LM, Roberts JS, Chen CA, Hiraki S, Green RC.

Eur J Hum Genet. 2010 Dec;18(12):1296-301. doi: 10.1038/ejhg.2010.119. Epub 2010 Jul 28.

3.

Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study.

Chao S, Roberts JS, Marteau TM, Silliman R, Cupples LA, Green RC.

Alzheimer Dis Assoc Disord. 2008 Jan-Mar;22(1):94-7. doi: 10.1097/WAD.0b013e31815a9dcc.

4.

Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease.

Cassidy MR, Roberts JS, Bird TD, Steinbart EJ, Cupples LA, Chen CA, Linnenbringer E, Green RC.

Alzheimers Dement. 2008 Nov;4(6):406-13. doi: 10.1016/j.jalz.2008.04.007.

5.

Genetic susceptibility testing versus family history-based risk assessment: Impact on perceived risk of Alzheimer disease.

LaRusse S, Roberts JS, Marteau TM, Katzen H, Linnenbringer EL, Barber M, Whitehouse P, Quaid K, Brown T, Green RC, Relkin NR.

Genet Med. 2005 Jan;7(1):48-53.

PMID:
15654228
6.

Disclosing the disclosure: factors associated with communicating the results of genetic susceptibility testing for Alzheimer's disease.

Ashida S, Koehly LM, Roberts JS, Chen CA, Hiraki S, Green RC.

J Health Commun. 2009 Dec;14(8):768-84. doi: 10.1080/10810730903295518.

7.

Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk.

Gooding HC, Linnenbringer EL, Burack J, Roberts JS, Green RC, Biesecker BB.

Patient Educ Couns. 2006 Dec;64(1-3):259-67. Epub 2006 Jul 21.

PMID:
16860524
8.

Effectiveness of a condensed protocol for disclosing APOE genotype and providing risk education for Alzheimer disease.

Roberts JS, Chen CA, Uhlmann WR, Green RC.

Genet Med. 2012 Aug;14(8):742-8. doi: 10.1038/gim.2012.37. Epub 2012 Apr 12.

9.

Predictive genetic testing for Alzheimer's disease: impact upon risk perception.

Marteau TM, Roberts S, LaRusse S, Green RC.

Risk Anal. 2005 Apr;25(2):397-404.

PMID:
15876213
10.

"I know what you told me, but this is what I think:" perceived risk of Alzheimer disease among individuals who accurately recall their genetics-based risk estimate.

Linnenbringer E, Roberts JS, Hiraki S, Cupples LA, Green RC.

Genet Med. 2010 Apr;12(4):219-27. doi: 10.1097/GIM.0b013e3181cef9e1.

11.

Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility.

Kopits IM, Chen C, Roberts JS, Uhlmann W, Green RC.

Genet Test Mol Biomarkers. 2011 Dec;15(12):871-5. doi: 10.1089/gtmb.2011.0028. Epub 2011 Jul 12.

12.

Decision-making about genetic testing among women at familial risk for breast cancer.

Jacobsen PB, Valdimarsdottier HB, Brown KL, Offit K.

Psychosom Med. 1997 Sep-Oct;59(5):459-66.

PMID:
9316177
13.

Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial.

Roberts JS, Barber M, Brown TM, Cupples LA, Farrer LA, LaRusse SA, Post SG, Quaid KA, Ravdin LD, Relkin NR, Sadovnick AD, Whitehouse PJ, Woodard JL, Green RC.

Genet Med. 2004 Jul-Aug;6(4):197-203.

PMID:
15266207
14.

Parental history of Alzheimer disease associated with lower plasma apolipoprotein E levels.

van Vliet P, Westendorp RG, Eikelenboom P, Comijs HC, Frölich M, Bakker E, van der Flier W, van Exel E.

Neurology. 2009 Sep 1;73(9):681-7. doi: 10.1212/WNL.0b013e3181b59c2e.

15.

BRCA1/2 test results impact risk management attitudes, intentions, and uptake.

O'Neill SC, Valdimarsdottir HB, Demarco TA, Peshkin BN, Graves KD, Brown K, Hurley KE, Isaacs C, Hecker S, Schwartz MD.

Breast Cancer Res Treat. 2010 Dec;124(3):755-64. doi: 10.1007/s10549-010-0881-4. Epub 2010 Apr 10.

16.

Effect of Alzheimer disease genetic risk disclosure on dietary supplement use.

Vernarelli JA, Roberts JS, Hiraki S, Chen CA, Cupples LA, Green RC.

Am J Clin Nutr. 2010 May;91(5):1402-7. doi: 10.3945/ajcn.2009.28981. Epub 2010 Mar 10.

17.
18.

Medicolegal, employment, and insurance issues in APOE genotyping and Alzheimer's disease.

Kapp MB.

Ann N Y Acad Sci. 1996 Dec 16;802:139-48. No abstract available.

PMID:
8993493
19.

Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.

Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, Minoshima S, Schwaiger M, Kurz A.

J Nucl Med. 2005 Oct;46(10):1625-32.

20.

Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior.

Zick CD, Mathews CJ, Roberts JS, Cook-Deegan R, Pokorski RJ, Green RC.

Health Aff (Millwood). 2005 Mar-Apr;24(2):483-90.

Supplemental Content

Support Center